PULSE BIOSCIENCES, INC. — Director's Dealing 2021

Mar 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pulse Biosciences, Inc. (PLSE)
CIK: 0001625101
Period of Report: 2020-12-09

Reporting Person: GARDINER SANDRA A. (CFO & EVP Admin. and Finance)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-09	Stock Option (right to buy)	$13.94	A	25961	Acquired	2029-11-18	Common Stock (25961)	Direct
2021-02-23	Stock Option (right to buy)	$10.66	A	8750	Acquired	2030-05-18	Common Stock (8750)	Direct
2021-03-22	Stock Option (right to buy)	$24.03	A	18000	Acquired	2031-03-22	Common Stock (18000)	Direct

Footnotes

F1: Represents the acquisition of vested options upon the determination of the Compensation Committee of the Board of Directors of the Issuer that certain performance conditions were met with respect to performance-based stock options granted to the Reporting Person on November 18, 2019.

F2: Represents the acquisition of vested options upon the determination of the Compensation Committee of the Board of Directors of the Issuer that certain performance conditions were met in 2020 with respect to performance-based stock options granted to the Reporting Person on May 18, 2020.

F3: The shares subject to the option will vest in equal annual installments over the following four years on the anniversary of March 1, 2021, subject to the Reporting Person's continued service through each vesting date.